In conclusion, this is the first report to describe behavioural effects of chronic treatments with different clinically used mood stabilizers in the AMPA receptor GluA1 subunit-deficient mice using test batteries specific to some hyperactive facets of bipolar illness, schizophrenia and schizoaffective disorder. Here, GRIA1 is linked to schizophrenia.